Nymox Pharmaceutical (Nymox Pharmaceutical) Interest Expense : $-0.06 Mil (TTM As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nymox Pharmaceutical's interest expense for the three months ended in Sep. 2023 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.06 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nymox Pharmaceutical's Operating Income for the three months ended in Sep. 2023 was $ -1.01 Mil. Nymox Pharmaceutical's Interest Expense for the three months ended in Sep. 2023 was $ -0.02 Mil. Nymox Pharmaceutical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nymox Pharmaceutical Interest Expense Historical Data

The historical data trend for Nymox Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Interest Expense Chart

Nymox Pharmaceutical Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-0.02

-0.04

Nymox Pharmaceutical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.03	-	-0.01	-0.02

Nymox Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

Nymox Pharmaceutical (OTCPK:NYMXF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nymox Pharmaceutical's Interest Expense for the three months ended in Sep. 2023 was $-0.02 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-1.01 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $0.00 Mil.

Nymox Pharmaceutical's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Nymox Pharmaceutical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel